<DOC>
	<DOCNO>NCT00219193</DOCNO>
	<brief_summary>To evaluate blood pressure lower effect safety triple combination aliskiren / valsartan / HCTZ ( 300/320/25 mg ) patient essential hypertension adequately responsive HCTZ 25 mg</brief_summary>
	<brief_title>A Clinical Study Evaluate Safety Efficacy Combination Aliskiren Valsartan Hypertensive Non Responders Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Inclusion Criteria Patients essential hypertension Patients eligible able participate study Exclusion Criteria Severe hypertension History evidence secondary form hypertension Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypertension , aliskiren , blood pressure , valsartan , HCTZ</keyword>
</DOC>